Estimation of SARS-CoV-2 infection fatality rate by real-time antibody

Screening of Blood Donors-

Profiling antibodies to SARS-CoV-2 can assist to evaluate potential immune response after COVID-19 illness. Luciferase IP system (LIPS) assay is a delicate methodology for quantitative detection of antibodies to antigens of their native conformation.

 

We right here describe LIPS to detect antibody responses to SARS-CoV-2 spike (S) and nucleocapsid (N) proteins in COVID-19 sufferers.

 

 

The antibodies focused each S and N fragments and gave a excessive assay sensitivity by figuring out 26 out of 26 COVID-19 sufferers with N antigen or with three protein fragments when mixed right into a single response.

 

The assay correlated nicely with ELISA methodology and was particular to COVID-19 as we noticed no reactivity amongst uninfected wholesome controls.

 

 

Our outcomes present that LIPS is a speedy and measurable methodology to display antibody responses in opposition to SARS-CoV-2 antigens.

 

 

Genscanner
Genscanner

 

Rabbit anti Human ESAM  Monoclonal Antibody

MBS2543874-02mL 0.2mL
EUR 550

Rabbit Anti-Human ESAM

102-PA42 100ug
EUR 240

Anti-Human ESAM Antibody

102-PA42AG 50 µg
EUR 157.5
Description: Endothelial cell-selective adhesion molecule (ESAM) is a 55 kDa type I transmembrane glycoprotein that belongs to the JAM family of immunoglobulin superfamily molecules. Human ESAM is synthesized as a 390 amino acid (aa) protein composed of a 29 aa signal peptide, a 216 aa extracellular region, a putative 26 aa transmembrane segment, and a 119 aa cytoplasmic domain. The extracellular region contains one V type and one C2 type Ig domain and is involved in homophilic adhesion. In the cytoplasmic domain, there is a docking site for the multifunctional adaptor protein MAGI. The extracellular region of human ESAM shows 90%, 74%, 69% and 67% aa identity with monkey, canine, mouse and rat extracellular ESAM, respectively. ESAM is expressed on endothelial cells, activated platelets and megakaryocytes, and can be found associated with cellto cell junctions. Whether ESAM is restricted to a particular junctional type is not clear. ESAM deficient mice have no defect in vascularization but do have reduced angiogenic potential. This may be due to a decreased migratory response to FGF-2.

Anti-Human ESAM Antibody

102-PA42S 100 µg
EUR 126
Description: Endothelial cell selective adhesion molecule (ESAM) is a 55 kDa type I transmembrane glycoprotein that belongs to the JAM family of immunoglobulin superfamily molecules. Human ESAM is synthesized as a 390 amino acid (aa) protein composed of a 29 aa signal peptide, a 216 aa extracellular region, a putative 26 aa transmembrane segment, and a 119 aa cytoplasmic domain. The extracellular region contains one V-type and one C2-type Ig domain and is involved in hemophilic adhesion. In the cytoplasmic domain, there is a docking site for the multifunctional adaptor protein MAGI1. The extracellular region of human ESAM shows 90%, 74%, 69% and 67% aa identity with monkey, canine, mouse and rat extracellular ESAM, respectively. ESAM is expressed on endothelial cells, activated platelets and megakaryocytes, and can be found associated with cell to cell junctions. Whether ESAM is restricted to a particular junctional type is not clear. ESAM deficient mice have no defect in vascularization but do have reduced angiogenic potential. This may be due to a decreased migratory response to FGF2.

Human ESAM siRNA

20-abx901776
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

ESAM siRNA (Human)

MBS8228277-15nmol 15nmol
EUR 405

ESAM siRNA (Human)

MBS8228277-30nmol 30nmol
EUR 565

ESAM siRNA (Human)

MBS8228277-5x30nmol 5x30nmol
EUR 2450

anti- ESAM antibody

FNab02860 100µg
EUR 658.5
Description: Antibody raised against ESAM

ESAM (untagged)-Human endothelial cell adhesion molecule (ESAM)

SC324152 10 µg Ask for price

ESAM (untagged)-Human endothelial cell adhesion molecule (ESAM)

SC120634 10 µg Ask for price

Human ESAM ELISA KIT

ELI-32729h 96 Tests
EUR 988.8

ESAM (NM_138961) Human Recombinant Protein

E45H40110M5 20 ug
EUR 785.42

ESAM (NM_138961) Human Recombinant Protein

PROTQ96AP7 20ug
EUR 1249
Description: Recombinant protein of human endothelial cell adhesion molecule (ESAM)

Human ESAM shRNA Plasmid

20-abx963997
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

ESAM ELISA KIT|Human

EF009449 96 Tests
EUR 826.8

ESAM (GFP-tagged) - Human endothelial cell adhesion molecule (ESAM)

RG203885 10 µg Ask for price

Human ESAM Protein Lysate

MBS8411229-002mg 0.02mg
EUR 365

Human ESAM Protein Lysate

MBS8411229-5x002mg 5x0.02mg
EUR 1410

Human ESAM Recombinant Protein

300-057 20 µg
EUR 84
Description: Endothelial cell selective adhesion molecule (ESAM) is a 55 kDa type I transmembrane glycoprotein that belongs to the JAM family of immunoglobulin superfamily molecules. Human ESAM is synthesized as a 390 amino acid (aa) protein composed of a 29 aa signal peptide, a 216 aa extracellular region, a putative 26 aa transmembrane segment, and a 119 aa cytoplasmic domain. The extracellular region contains one V-type and one C2-type Ig domain and is involved in hemophilic adhesion. In the cytoplasmic domain, there is a docking site for the multifunctional adaptor protein MAGI1. The extracellular region of human ESAM shows 90%, 74%, 69% and 67% aa identity with monkey, canine, mouse and rat extracellular ESAM, respectively. ESAM is expressed on endothelial cells, activated platelets and megakaryocytes, and can be found associated with cell to cell junctions. Whether ESAM is restricted to a particular junctional type is not clear. ESAM deficient mice have no defect in vascularization but do have reduced angiogenic potential. This may be due to a decreased migratory response to FGF2. Soluble ESAM is fused to a C-terminal His-tag (6x His).

Recombinant Human ESAM Protein

E30P01830A 50 ug
EUR 295

Recombinant Human ESAM Protein

MBS8248993-001mg 0.01mg
EUR 205

Recombinant Human ESAM Protein

MBS8248993-005mg 0.05mg
EUR 390

Recombinant Human ESAM Protein

MBS8248993-05mg 0.5mg
EUR 2510

Recombinant Human ESAM Protein

MBS8248993-5x05mg 5x0.5mg
EUR 11220

Recombinant Human ESAM Protein

MBS8248994-001mg 0.01mg
EUR 230

Recombinant Human ESAM Protein

MBS8248994-005mg 0.05mg
EUR 480

Recombinant Human ESAM Protein

MBS8248994-05mg 0.5mg
EUR 2825

Recombinant Human ESAM Protein

MBS8248994-5x05mg 5x0.5mg
EUR 12640

Recombinant Human ESAM Protein

PKSH031780-100ug 100ug
EUR 732
Description: Human

ESAM (Myc-DDK-tagged)-Human endothelial cell adhesion molecule (ESAM)

RC203885 10 µg Ask for price

ESAM (NM_138961) Human Over-expression Lysate

E45H13940-2 each
EUR 395

ESAM (NM_138961) Human Over-expression Lysate

LS090952 100ug
EUR 628
Description: Transient overexpression lysate of endothelial cell adhesion molecule (ESAM)

ESAM Protein, Human, Recombinant

E45H51490M0-100 100 ug
EUR 1046.77

ESAM Protein, Human, Recombinant

MBS8120072-01mg 0.1mg
EUR 395

ESAM Protein, Human, Recombinant

MBS8120072-5x01mg 5x0.1mg
EUR 1635

ESAM Recombinant Protein (Human)

RP010933 100 ug Ask for price

Human ESAM Protein, Fc Tag

E40KMPH1320 20ug
EUR 495

Human ESAM Protein, Fc Tag

E40KMPH1322 20ug
EUR 495

Human ESAM Protein, Fc Tag

E40KMPH6469 20ug
EUR 495

 

LIPS methodology for the detection of SARS-CoV-2 antibodies to spike and nucleocapsid proteins

 

Background: The pandemic on account of extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has large penalties for our societies.
Information of the seroprevalence of SARS-CoV-2 is required to precisely monitor the unfold of the epidemic and to calculate the an infection fatality charge (IFR). These measures could assist the authorities to make knowledgeable selections and modify the present societal interventions.
The target was to carry out nationwide real-time seroprevalence surveying amongst blood donors as a software to estimate earlier SARS-CoV-2 infections and the inhabitants primarily based IFR.
Strategies: Danish blood donors aged 17-69 years giving blood April 6 to Might Three had been examined for SARS-CoV-2 immunoglobulin M and G antibodies utilizing a business lateral move check.
Antibody standing was in contrast between geographical areas and an estimate of the IFR was calculated. The seroprevalence was adjusted for assay sensitivity and specificity taking the uncertainties of the check validation under consideration when reporting the 95% confidence intervals (CI).
Outcomes: The primary 20,640 blood donors had been examined and a mixed adjusted seroprevalence of 1.9% (CI: 0.8-2.3) was calculated. The seroprevalence differed throughout areas.
Utilizing accessible knowledge on fatalities and inhabitants numbers a mixed IFR in sufferers youthful than 70 is estimated at 89 per 100,000 (CI: 72-211) infections.
Conclusions: The IFR was estimated to be barely decrease than beforehand reported from different international locations not utilizing seroprevalence knowledge. The IFR is probably going a number of fold decrease than the present estimate.

Recombinant Rhizopus oryzae Lipase

MBS1233380-002mgYeast 0.02mg(Yeast)
EUR 965

Recombinant Rhizopus oryzae Lipase

MBS1233380-01mgEColi 0.1mg(E-Coli)
EUR 985

Recombinant Rhizopus oryzae Lipase

MBS1233380-01mgYeast 0.1mg(Yeast)
EUR 1130

Recombinant Rhizopus oryzae Glucoamylase 1

MBS1229312-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1355

Recombinant Rhizopus oryzae Glucoamylase 1

MBS1229312-002mgEColi 0.02mg(E-Coli)
EUR 1055

Recombinant Rhizopus oryzae Glucoamylase 1

MBS1229312-002mgYeast 0.02mg(Yeast)
EUR 1125

Recombinant Rhizopus oryzae Glucoamylase 1

MBS1229312-01mgEColi 0.1mg(E-Coli)
EUR 1230

Recombinant Rhizopus oryzae Glucoamylase 1

MBS1229312-01mgYeast 0.1mg(Yeast)
EUR 1310

Recombinant Rhizopus oryzae Cytochrome b (cob), partial

MBS7079456-INQUIRE INQUIRE Ask for price

Recombinant Rhizopus oryzae FK506-binding protein 2A (FKBP2)

MBS7014832-002mg 0.02mg
EUR 1420

Recombinant Rhizopus oryzae FK506-binding protein 2A (FKBP2)

MBS7014832-01mg 0.1mg
EUR 2385

Recombinant Rhizopus oryzae FK506-binding protein 2A (FKBP2)

MBS7014832-5x01mg 5x0.1mg
EUR 10680

Recombinant Rhizopus oryzae FK506-binding protein 2B (FKBP3)

MBS7014834-002mg 0.02mg
EUR 1475

Recombinant Rhizopus oryzae FK506-binding protein 2B (FKBP3)

MBS7014834-01mg 0.1mg
EUR 2435

Recombinant Rhizopus oryzae FK506-binding protein 2B (FKBP3)

MBS7014834-5x01mg 5x0.1mg
EUR 10915

Recombinant Rhizopus oryzae FK506-binding protein 2A (FKBP2)

MBS1077988-INQUIRE INQUIRE Ask for price

Recombinant Rhizopus oryzae FK506-binding protein 4 (FKBP4)

MBS1178969-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1255

Recombinant Rhizopus oryzae FK506-binding protein 4 (FKBP4)

MBS1178969-002mgEColi 0.02mg(E-Coli)
EUR 925

Recombinant Rhizopus oryzae FK506-binding protein 4 (FKBP4)

MBS1178969-002mgYeast 0.02mg(Yeast)
EUR 1045

Recombinant Rhizopus oryzae FK506-binding protein 4 (FKBP4)

MBS1178969-01mgEColi 0.1mg(E-Coli)
EUR 1110

Recombinant Rhizopus oryzae FK506-binding protein 4 (FKBP4)

MBS1178969-01mgYeast 0.1mg(Yeast)
EUR 1190

Recombinant Rhizopus oryzae FK506-binding protein 1 (FKBP1)

MBS1238540-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1030

Recombinant Rhizopus oryzae FK506-binding protein 1 (FKBP1)

MBS1238540-002mgEColi 0.02mg(E-Coli)
EUR 605

Recombinant Rhizopus oryzae FK506-binding protein 1 (FKBP1)

MBS1238540-002mgYeast 0.02mg(Yeast)
EUR 785

Recombinant Rhizopus oryzae FK506-binding protein 1 (FKBP1)

MBS1238540-01mgEColi 0.1mg(E-Coli)
EUR 705

Recombinant Rhizopus oryzae FK506-binding protein 1 (FKBP1)

MBS1238540-01mgYeast 0.1mg(Yeast)
EUR 915

Recombinant Rhizopus oryzae FK506-binding protein 2B (FKBP3)

MBS1235608-INQUIRE INQUIRE Ask for price

Recombinant Rhizopus oryzae FK506-binding protein 5 (FKBP5)

MBS1156059-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1260

Recombinant Rhizopus oryzae FK506-binding protein 5 (FKBP5)

MBS1156059-002mgEColi 0.02mg(E-Coli)
EUR 925

Recombinant Rhizopus oryzae FK506-binding protein 5 (FKBP5)

MBS1156059-002mgYeast 0.02mg(Yeast)
EUR 1050

Recombinant Rhizopus oryzae FK506-binding protein 5 (FKBP5)

MBS1156059-01mgEColi 0.1mg(E-Coli)
EUR 1115

Recombinant Rhizopus oryzae FK506-binding protein 5 (FKBP5)

MBS1156059-01mgYeast 0.1mg(Yeast)
EUR 1195

Recombinant Rhizopus oryzae L-lactate dehydrogenase B (LDHB)

MBS1333447-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1180

Recombinant Rhizopus oryzae L-lactate dehydrogenase B (LDHB)

MBS1333447-002mgEColi 0.02mg(E-Coli)
EUR 825

Recombinant Rhizopus oryzae L-lactate dehydrogenase B (LDHB)

MBS1333447-002mgYeast 0.02mg(Yeast)
EUR 970

Recombinant Rhizopus oryzae L-lactate dehydrogenase B (LDHB)

MBS1333447-01mgEColi 0.1mg(E-Coli)
EUR 990

Recombinant Rhizopus oryzae L-lactate dehydrogenase B (LDHB)

MBS1333447-01mgYeast 0.1mg(Yeast)
EUR 1135

Recombinant Rhizopus oryzae L-lactate dehydrogenase A (LDHA)

MBS1438928-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1195

Recombinant Rhizopus oryzae L-lactate dehydrogenase A (LDHA)

MBS1438928-002mgEColi 0.02mg(E-Coli)
EUR 850

Recombinant Rhizopus oryzae L-lactate dehydrogenase A (LDHA)

MBS1438928-002mgYeast 0.02mg(Yeast)
EUR 990

Recombinant Rhizopus oryzae L-lactate dehydrogenase A (LDHA)

MBS1438928-01mgEColi 0.1mg(E-Coli)
EUR 1020

Recombinant Rhizopus oryzae L-lactate dehydrogenase A (LDHA)

MBS1438928-01mgYeast 0.1mg(Yeast)
EUR 1125

Recombinant Rhizopus oryzae Orotidine 5'-phosphate decarboxylase (pyrG)

MBS1324181-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1145

Recombinant Rhizopus oryzae Orotidine 5'-phosphate decarboxylase (pyrG)

MBS1324181-002mgEColi 0.02mg(E-Coli)
EUR 780

Recombinant Rhizopus oryzae Orotidine 5'-phosphate decarboxylase (pyrG)

MBS1324181-002mgMammalianCell 0.02mg(Mammalian-Cell)
EUR 1410

Recombinant Rhizopus oryzae Orotidine 5'-phosphate decarboxylase (pyrG)

MBS1324181-01mgBaculovirus 0.1mg(Baculovirus)
EUR 1645

Recombinant Rhizopus oryzae Orotidine 5'-phosphate decarboxylase (pyrG)

MBS1324181-01mgEColi 0.1mg(E-Coli)
EUR 935

Recombinant Rhizopus oryzae FK506-binding protein 2A (FKBP2), partial

MBS7059116-INQUIRE INQUIRE Ask for price

Recombinant Rhizopus oryzae FK506-binding protein 2B (FKBP3), partial

MBS7059130-INQUIRE INQUIRE Ask for price

Recombinant Rhizopus oryzae ATP synthase subunit 9, mitochondrial (atp9)

MBS7008546-002mg 0.02mg
EUR 1335

Recombinant Rhizopus oryzae ATP synthase subunit 9, mitochondrial (atp9)

MBS7008546-01mg 0.1mg
EUR 2300

Recombinant Rhizopus oryzae ATP synthase subunit 9, mitochondrial (atp9)

MBS7008546-5x01mg 5x0.1mg
EUR 10300

Recombinant Rhizopus oryzae Peptidyl-prolyl isomerase cwc27 (cwc27), partial

MBS1162708-INQUIRE INQUIRE Ask for price

Recombinant Rhizopus oryzae Peptidyl-prolyl cis-trans isomerase A1 (cyp2)

MBS1006719-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1085

Recombinant Rhizopus oryzae Peptidyl-prolyl cis-trans isomerase A1 (cyp2)

MBS1006719-002mgEColi 0.02mg(E-Coli)
EUR 675

Recombinant Rhizopus oryzae Peptidyl-prolyl cis-trans isomerase A1 (cyp2)

MBS1006719-002mgYeast 0.02mg(Yeast)
EUR 840

Recombinant Rhizopus oryzae Peptidyl-prolyl cis-trans isomerase A1 (cyp2)

MBS1006719-01mgEColi 0.1mg(E-Coli)
EUR 785

Recombinant Rhizopus oryzae Peptidyl-prolyl cis-trans isomerase A1 (cyp2)

MBS1006719-01mgYeast 0.1mg(Yeast)
EUR 980

Recombinant Rhizopus oryzae Peptidyl-prolyl cis-trans isomerase H (cyp7)

MBS1036725-002mgBaculovirus 0.02mg(Baculovirus)
EUR 1100

Recombinant Rhizopus oryzae Peptidyl-prolyl cis-trans isomerase H (cyp7)

MBS1036725-002mgEColi 0.02mg(E-Coli)
EUR 695

We now have initiated real-time nationwide anti-SARS-CoV-2 seroprevalence surveying of blood donations as a software in monitoring the epidemic.

Serial Neuropsychological Testing in MOG Antibody-Related Illness To Enhance Understanding of Outcomes

 

Neurocognitive outcomes knowledge in sufferers with myelin oligodendrocyte glycoprotein (MOG) antibody-associated illness are restricted. Inside MOG-positive cohorts, outcomes knowledge usually make the most of gross psychological, cognitive, or bodily incapacity measures.

 

 

Right here, we report a pediatric affected person who offered with two clinically heterogeneous occasions and was discovered to have MOG-associated encephalomyelitis. We administered detailed neuropsychological check batteries to acquire a sturdy understanding of the affected person’s neurocognitive profile over time.

 

 

This case exemplifies the necessity to carry out systematic and serial neuropsychological testing in sufferers with MOG-associated illness to higher perceive neurocognitive outcomes, facilitate multidisciplinary administration, and enhance restoration.